Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation, AutologousTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation ChimeraTissue DonorsBone MarrowTreatment OutcomeGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityHistocompatibility TestingGraft SurvivalRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticStem CellsMyelodysplastic SyndromesRemission InductionVidarabineImmunosuppressive AgentsCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsCombined Modality TherapyTransplantation, IsogeneicLiver TransplantationSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTime FactorsSurvival RateSurvival AnalysisTransplantation ImmunologyHematopoiesisCytomegalovirus InfectionsCyclophosphamideAcute DiseaseT-LymphocytesLymphocyte DepletionDisease-Free SurvivalSevere Combined ImmunodeficiencyMice, Inbred C57BLMultiple MyelomaFollow-Up StudiesOpportunistic InfectionsFlow CytometryCystitisHematopoietic Stem Cell MobilizationMinor Histocompatibility AntigensAntigens, CD34Leukemia, MyeloidImmunosuppressionLeukemic InfiltrationSalvage TherapyAntilymphocyte SerumNeoplasm, ResidualKidney TransplantationLymphoproliferative DisordersAntineoplastic Combined Chemotherapy ProtocolsGraft RejectionBone and BonesCell DifferentiationCytomegalovirusPrognosisImmunocompromised HostBone Marrow PurgingFatal OutcomeBronchiolitis ObliteransRisk FactorsBlood Group IncompatibilityCytarabineCyclosporineMelphalanCell TransplantationColony-Forming Units AssayLymphoma, Non-HodgkinMycosesMesenchymal Stem Cell TransplantationPrimary MyelofibrosisGranulocyte Colony-Stimulating FactorGanciclovirCell LineageRadiation Chimera